

## Commercial and Other Pharmacy Program Updates

The following changes to our pharmacy programs will become effective **April 1, 2022**. These changes affect our preferred drug lists and medication guides, including prior authorization requirements, the Responsible Quantity Program, Responsible Steps and the Pharmacy Coverage Exclusions List. Important changes are summarized below.

### Medications Requiring Prior Authorization

Prior authorization requirements for the following list of medications will change under the member's pharmacy benefits. This applies only to members whose plans are part of the Prior Authorization Program. New-to-market drugs may still be under review for a coverage decision as part of our New-to-Market Program.

Drugs Added to the Prior Authorization Program	
Drug	Covered Condition(s)*
Adbry	FDA approved indication(s)
Basremi SC	FDA approved indication(s)
Epclusa pellet pack	FDA approved indication(s)
Livtensity	FDA approved indication(s)
Mavyret pellet pack	FDA approved indication(s)
Oplezura	FDA approved indication(s)
Oxbryta	FDA approved indication(s)
Purified Cortrophin gel	FDA approved indication(s)
Recorlev	FDA approved indication(s)
Ryplazim	FDA approved indication(s)
Scemblix	FDA approved indication(s)
Skytrofa	FDA approved indication(s)
Tarpeyo	FDA approved indication(s)
Tascenso ODT	FDA approved indication(s)
Tavneos	FDA approved indication(s)
Voxzgo	FDA approved indication(s)
*Summary of criteria and additional information are available with our authorization forms.	

<sup>1</sup>Availity, LLC is a multi-payer joint venture company. For more information, visit [availity.com](http://availity.com).

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

## Responsible Quantity Program

We will add the following drugs and drug-dispensing limits to the Responsible Quantity Program effective April 1, 2022. This applies only to members whose plans are part of the Responsible Quantity Program.

**Please note:** Responsible Quantity Program limits apply to generic drugs where applicable.

Drugs Added to the Responsible Quantity Program	
Brand/Generic Name	Dispensing Limit Per Month (unless noted otherwise)
Biktarvy	30 tabs
Dupixent 100mg	2 syringes / 28 days
Epclusa pellet pack	30 packets
Mavyret pellet pack	150 packets
Molnupiravir	1 treatment course
Oplezura	60 grams
Oxbryta	90 tabs
Paxlovid	1 treatment course
Changes to Drugs Already in the Responsible Quantity Program	
Meperidine 50mg tabs	12 tablets per day

## New Pharmacy Coverage Exclusions

Our commercial pharmacy plans will no longer cover the brand-name or generic drugs listed below. We will cover many of their therapeutic or generic alternatives. This exclusion list applies only to members enrolled in health plans that allow pharmacy coverage exclusions.

New Coverage Exclusions	
Cephalexin 750mg	Cyclosporin ophthalmic emulsion
Hydroxychloroquine 100mg, 300mg, 400mg	Loreev XR
Restasis Multidose	Sertraline 150 mg, 200 mg
Stalevo 50 mg, 75 mg, 100 mg	Stalevo 125 mg, 150 mg, 200 mg
Drugs added back to Coverage	
Calcipotriene-betamethasone susp and ointment	Firdapse

## Preferred Drug List Changes and Medication Guides

Changes to our preferred drug lists and the current list are available at [floridablue.com/providers](https://floridablue.com/providers). Select **Tools & Resources, Medical & Pharmacy Policies, Guidelines** and then **Medication Guides**. Here is the direct link to the [Medication Guides](#).

## Net Results Formulary Program Updates

The following changes only apply to members with the Net Results Formulary as part of their plan.

## Net Results Pharmacy Coverage Exclusions

Effective April 1, 2022, Net Results will no longer cover the brand-name or generic drugs listed below.

Net Results New Exclusions	
Brinzolamide 1%	Brovama
Bystolic	Calcipotriene ointment
Cyclosporine ophthalmic	Epaned suspension
Hydroxychloroquine 100 mg, 300 mg, 400 mg	Icosapent ethyl
Imiquimod cream	Intelence
Isosorbide dinitrate 40 mg	Loreev XR
Lybalvi	Mytesi
Opzelura	Pimecrolimus cream
Prednisolone phosphate ODT	Quilpta
Restasis multidose	Sertraline 150 mg, 200 mg
Skytrofa	Sutent
Trudhesa	Zolpidem SL tab
Net Results Drugs Added Back to Coverage	
Gemtesa	Myfembree

## Net Results Quantity Limit Program

The following drugs and drug-dispensing limits to the Net Results Quantity Limit Program become effective April 1, 2022.

Brand/Generic Name	Net Results Quantity per 30-day supply unless otherwise indicated
Besremi	2 syringes / 28 days
Epclusa packet	30 packets
Mavyret packet	150 packets
Oxbryta	150 tablets
Reset	1 license / 90 days
Reset-O	1 license / 84 days
Scemblix 20mg, 40 mg	60 tabs, 300 tabs
Sertraline	30 capsules
Quilpta	30 tablets

## Net Results Medications Requiring Prior Authorization

Prior authorization requirements for the following list of medications will change for members using our Net Results Formulary effective April 1, 2022.

Drugs Added to the Net Results Prior Authorization Program	
Drug	Covered Condition(s)*
Besremi	FDA approved indication (s)
Bylvay	FDA approved indication (s)
Cortrophin gel	FDA approved indication (s)
Dupixent 100mg	FDA approved indication (s)
Epclusa packets	FDA approved indication (s)
Livmarli	FDA approved indication (s)
Mavyret packets	FDA approved indication (s)
Oxbryta	FDA approved indication (s)
Qulipta	FDA approved indication (s)
Scemblix	FDA approved indication (s)
Skytrofa	FDA approved indication (s)
*Summary of criteria and additional information are available with authorization forms available at <a href="http://myprime.com">myprime.com</a>	

## Net Results Step Therapy Program Changes

The following changes apply to the Net Results Step Therapy Program.

Program	Program Change
Antidepressant	Addition of sertraline as a target
Oral NSAID	Addition of Elyxyb as a target

## Net Results Authorization Request Forms

Net Results authorization request forms are available at [myprime.com](http://myprime.com). Create a profile or click on **Forms** and then select **Continue without signing in**. Select **Florida Blue** from the top drop-down menu and **No** to the question regarding Medicare status. At the top of the following page, click **Forms** and then select **Florida Blue Net Results Formulary**. You will see a list of form categories.

## Verify Eligibility and Benefits on Availity

As a reminder, you can verify your patients' eligibility and pharmacy benefits through Availity<sup>®1</sup> at [availity.com](http://availity.com). If you have questions about your patients' Florida Blue benefits or these pharmacy updates, please call the Provider Contact Center at 800-727-2227.